Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Blast Crisis 1

Interventions

Cyclophosphamide 48fludarabine 32Methotrexate 24blinatumomab 20fludarabine phosphate 19Dexamethasone 19Vincristine 18Whole-Body Irradiation 16Specimen Handling 16Cytarabine 16Tacrolimus 14Mycophenolic Acid 14Peripheral Blood Stem Cell Transplantation 13Melphalan 13Mercaptopurine 12Calcium Dobesilate 12merphos 11Busulfan 11Biopsy 11Magnetic Resonance Spectroscopy 10Etoposide 10Stem Cell Transplantation 9Prednisone 9Granulocyte Colony-Stimulating Factor 9Cyclosporine 9Thiotepa 8Rituximab 8Mesna 8Filgrastim 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × asciminib × 90 days × Clear all
NCT07387926 2026-05-19

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

Novartis

Phase 1/2 Not yet recruiting
50 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06308588 2026-05-15

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡